{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T23:38:17Z","timestamp":1785541097483,"version":"3.56.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-025-04625-9","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T02:01:57Z","timestamp":1751335317000},"page":"4301-4308","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["SGLT2 inhibitors do not cause de novo urinary incontinence in diabetic female patients with chronic kidney disease"],"prefix":"10.1007","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1382-2439","authenticated-orcid":false,"given":"\u00d6zant","family":"Helvac\u0131","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7358-6599","authenticated-orcid":false,"given":"Ay\u015feg\u00fcl","family":"Karao\u011flan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8356-4463","authenticated-orcid":false,"given":"Bur\u00e7ak Cavnar","family":"Helvac\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9146-2133","authenticated-orcid":false,"given":"Galip","family":"G\u00fcz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8343-7432","authenticated-orcid":false,"given":"Hatice","family":"Pa\u015fao\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"issue":"10365","key":"4625_CR1","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","volume":"400","author":"Nuffield Department of Population Health Renal Studies G, Consortium SiM-AC-RT","year":"2022","unstructured":"Nuffield Department of Population Health Renal Studies G, Consortium SiM-AC-RT (2022) Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet 400(10365):1788\u20131801. https:\/\/doi.org\/10.1016\/S0140-6736(22)02074-8","journal-title":"Lancet"},{"issue":"1","key":"4625_CR2","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12933-022-01455-2","volume":"21","author":"HM Salah","year":"2022","unstructured":"Salah HM, Al\u2019Aref SJ, Khan MS, Al-Hawwas M, Vallurupalli S, Mehta JL et al (2022) Efficacy and safety of sodium-glucose cotransporter 2 inhibitors initiation in patients with acute heart failure, with and without type 2 diabetes: a systematic review and meta-analysis. Cardiovasc Diabetol 21(1):20. https:\/\/doi.org\/10.1186\/s12933-022-01455-2","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"4625_CR3","doi-asserted-by":"publisher","first-page":"101508","DOI":"10.1016\/j.diabet.2023.101508","volume":"50","author":"AJ Scheen","year":"2024","unstructured":"Scheen AJ (2024) Cardiovascular protection significantly depends on HbA1c improvement with GLP-1RAs but not with SGLT2 is in type 2 diabetes: a narrative review. Diabetes Metab 50(2):101508. https:\/\/doi.org\/10.1016\/j.diabet.2023.101508","journal-title":"Diabetes Metab"},{"issue":"11","key":"4625_CR4","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.1007\/s11255-023-03645-7","volume":"55","author":"ME Demir","year":"2023","unstructured":"Demir ME, \u00d6zler TE, Merhametsiz \u00d6, S\u00f6zener U, Uyar M, Ercan Z et al (2023) The results of SGLT-2 inhibitors use in kidney transplantation: 1-year experiences from two centers. Int Urol Nephrol 55(11):2989\u20132999. https:\/\/doi.org\/10.1007\/s11255-023-03645-7","journal-title":"Int Urol Nephrol"},{"issue":"5","key":"4625_CR5","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1111\/dom.13648","volume":"21","author":"T Toyama","year":"2019","unstructured":"Toyama T, Neuen BL, Jun M, Ohkuma T, Neal B, Jardine MJ et al (2019) Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and meta-analysis. Diabetes Obes Metab 21(5):1237\u20131250. https:\/\/doi.org\/10.1111\/dom.13648","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"4625_CR6","doi-asserted-by":"publisher","first-page":"751","DOI":"10.34067\/KID.0000472021","volume":"2","author":"N Krepostman","year":"2021","unstructured":"Krepostman N, Kramer H (2021) Lower urinary tract symptoms should be queried when initiating sodium glucose cotransporter 2 inhibitors. Kidney360 2(4):751\u2013754. https:\/\/doi.org\/10.34067\/KID.0000472021","journal-title":"Kidney360"},{"key":"4625_CR7","unstructured":"Tran LN, Puckett Y (2024) Urinary incontinence. StatPearls. Treasure Island (FL) ineligible companies. Disclosure: Yana Puckett declares no relevant financial relationships with ineligible companies."},{"issue":"16","key":"4625_CR8","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1001\/jama.2017.12137","volume":"318","author":"ES Lukacz","year":"2017","unstructured":"Lukacz ES, Santiago-Lastra Y, Albo ME, Brubaker L (2017) Urinary incontinence in women: a review. JAMA 318(16):1592\u20131604. https:\/\/doi.org\/10.1001\/jama.2017.12137","journal-title":"JAMA"},{"issue":"3","key":"4625_CR9","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1111\/aogs.14027","volume":"100","author":"MAH Hage-Fransen","year":"2021","unstructured":"Hage-Fransen MAH, Wiezer M, Otto A, Wieffer-Platvoet MS, Slotman MH, Nijhuis-van der Sanden MWG et al (2021) Pregnancy- and obstetric-related risk factors for urinary incontinence, fecal incontinence, or pelvic organ prolapse later in life: a systematic review and meta-analysis. Acta Obstet Gynecol Scand 100(3):373\u2013382. https:\/\/doi.org\/10.1111\/aogs.14027","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"8","key":"4625_CR10","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1002\/nau.20635","volume":"27","author":"S Hunskaar","year":"2008","unstructured":"Hunskaar S (2008) A systematic review of overweight and obesity as risk factors and targets for clinical intervention for urinary incontinence in women. Neurourol Urodyn 27(8):749\u2013757. https:\/\/doi.org\/10.1002\/nau.20635","journal-title":"Neurourol Urodyn"},{"issue":"8","key":"4625_CR11","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1007\/s00192-009-0888-8","volume":"20","author":"Y Izci","year":"2009","unstructured":"Izci Y, Topsever P, Filiz TM, Cinar ND, Uludag C, Lagro-Janssen T (2009) The association between diabetes mellitus and urinary incontinence in adult women. Int Urogynecol J Pelvic Floor Dysfunct 20(8):947\u2013952. https:\/\/doi.org\/10.1007\/s00192-009-0888-8","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"},{"key":"4625_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20030629","author":"TM Ansary","year":"2019","unstructured":"Ansary TM, Nakano D, Nishiyama A (2019) Diuretic effects of sodium glucose cotransporter 2 inhibitors and their influence on the renin-angiotensin system. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms20030629","journal-title":"Int J Mol Sci"},{"key":"4625_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/medicines9120059","author":"S Uitrakul","year":"2022","unstructured":"Uitrakul S, Aksonnam K, Srivichai P, Wicheannarat S, Incomenoy S (2022) The incidence and risk factors of urinary tract infection in patients with type 2 diabetes mellitus using SGLT2 inhibitors: a real-world observational study. Medicines. https:\/\/doi.org\/10.3390\/medicines9120059","journal-title":"Medicines"},{"issue":"4","key":"4625_CR14","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1002\/nau.20041","volume":"23","author":"K Avery","year":"2004","unstructured":"Avery K, Donovan J, Peters TJ, Shaw C, Gotoh M, Abrams P (2004) ICIQ: a brief and robust measure for evaluating the symptoms and impact of urinary incontinence. Neurourol Urodyn 23(4):322\u2013330. https:\/\/doi.org\/10.1002\/nau.20041","journal-title":"Neurourol Urodyn"},{"issue":"5","key":"4625_CR15","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1097\/00001703-199510000-00016","volume":"7","author":"CJ Kelleher","year":"1995","unstructured":"Kelleher CJ, Cardozo LD, Toozs-Hobson PM (1995) Quality of life and urinary incontinence. Curr Opin Obstet Gynecol 7(5):404\u2013408","journal-title":"Curr Opin Obstet Gynecol"},{"issue":"1","key":"4625_CR16","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/nau.20292","volume":"26","author":"C Cam","year":"2007","unstructured":"Cam C, Sakalli M, Ay P, Cam M, Karateke A (2007) Validation of the short forms of the incontinence impact questionnaire (IIQ-7) and the urogenital distress inventory (UDI-6) in a Turkish population. Neurourol Urodyn 26(1):129\u2013133. https:\/\/doi.org\/10.1002\/nau.20292","journal-title":"Neurourol Urodyn"},{"key":"4625_CR17","doi-asserted-by":"publisher","first-page":"616","DOI":"10.3389\/fendo.2020.00616","volume":"11","author":"LS Santos-Baez","year":"2020","unstructured":"Santos-Baez LS, Ginsberg HN (2020) Hypertriglyceridemia-causes, significance, and approaches to therapy. Front Endocrinol 11:616. https:\/\/doi.org\/10.3389\/fendo.2020.00616","journal-title":"Front Endocrinol"},{"issue":"4","key":"4625_CR18","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.maturitas.2014.01.009","volume":"77","author":"C Wang","year":"2014","unstructured":"Wang C, Wan X, Wang K, Li J, Sun T, Guan X (2014) Disease stigma and intentions to seek care for stress urinary incontinence among community-dwelling women. Maturitas 77(4):351\u2013355. https:\/\/doi.org\/10.1016\/j.maturitas.2014.01.009","journal-title":"Maturitas"},{"issue":"Suppl 1","key":"4625_CR19","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.2337\/dc23-S002","volume":"46","author":"NA ElSayed","year":"2023","unstructured":"ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D et al (2023) 2. classification and diagnosis of diabetes: standards of care in diabetes-2023. Diabetes Care 46(Suppl 1):S19\u2013S40. https:\/\/doi.org\/10.2337\/dc23-S002","journal-title":"Diabetes Care"},{"issue":"4S","key":"4625_CR20","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"Kidney Disease: Improving Global Outcomes CKDWG","year":"2024","unstructured":"Kidney Disease: Improving Global Outcomes CKDWG (2024) KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 105(4S):S117\u2013S314. https:\/\/doi.org\/10.1016\/j.kint.2023.10.018","journal-title":"Kidney Int"},{"issue":"8","key":"4625_CR21","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.34067\/KID.0006482020","volume":"2","author":"ER Argaiz","year":"2021","unstructured":"Argaiz ER, Koratala A, Reisinger N (2021) Comprehensive assessment of fluid status by point-of-care ultrasonography. Kidney360 2(8):1326\u20131338. https:\/\/doi.org\/10.34067\/KID.0006482020","journal-title":"Kidney360"},{"issue":"2","key":"4625_CR22","doi-asserted-by":"publisher","first-page":"236","DOI":"10.4103\/0970-1591.65398","volume":"26","author":"KC Moore","year":"2010","unstructured":"Moore KC, Lucas MG (2010) Management of male urinary incontinence. Indian J Urol 26(2):236\u2013244. https:\/\/doi.org\/10.4103\/0970-1591.65398","journal-title":"Indian J Urol"},{"issue":"16","key":"4625_CR23","doi-asserted-by":"publisher","first-page":"2850","DOI":"10.1002\/sim.6148","volume":"33","author":"MW Fagerland","year":"2014","unstructured":"Fagerland MW, Lydersen S, Laake P (2014) Recommended tests and confidence intervals for paired binomial proportions. Stat Med 33(16):2850\u20132875. https:\/\/doi.org\/10.1002\/sim.6148","journal-title":"Stat Med"},{"issue":"6975","key":"4625_CR24","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1136\/bmj.310.6975.298","volume":"310","author":"DG Altman","year":"1995","unstructured":"Altman DG, Bland JM (1995) Statistics notes: the normal distribution. BMJ 310(6975):298. https:\/\/doi.org\/10.1136\/bmj.310.6975.298","journal-title":"BMJ"},{"issue":"1","key":"4625_CR25","doi-asserted-by":"publisher","first-page":"e0208631","DOI":"10.1371\/journal.pone.0208631","volume":"14","author":"J Miller","year":"2019","unstructured":"Miller J, Ulrich R (2019) The quest for an optimal alpha. PLoS ONE 14(1):e0208631. https:\/\/doi.org\/10.1371\/journal.pone.0208631","journal-title":"PLoS ONE"},{"issue":"2","key":"4625_CR26","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/pdi.2160","volume":"35","author":"J Shikuma","year":"2018","unstructured":"Shikuma J, Ito R, Sasaki-Shima J, Teshima A, Hara K, Takahashi T et al (2018) Changes in overactive bladder symptoms after sodium glucose cotransporter-2 inhibitor administration to patients with type 2 diabetes. Pract Diabetes 35(2):47\u201350. https:\/\/doi.org\/10.1002\/pdi.2160","journal-title":"Pract Diabetes"},{"issue":"5","key":"4625_CR27","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1002\/cpt.3182","volume":"115","author":"S Bea","year":"2024","unstructured":"Bea S, Lee H, Park S, Cho YM, Choi WS, Bykov K et al (2024) Concomitant use of sodium-glucose cotransporter 2 inhibitors and overactive bladder drugs and the risk of urinary tract infection. Clin Pharmacol Ther 115(5):1132\u20131140. https:\/\/doi.org\/10.1002\/cpt.3182","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"4625_CR28","doi-asserted-by":"publisher","first-page":"101285","DOI":"10.1016\/j.diabet.2021.101285","volume":"47","author":"P Delanaye","year":"2021","unstructured":"Delanaye P, Scheen AJ (2021) The diuretic effects of SGLT2 inhibitors: a comprehensive review of their specificities and their role in renal protection. Diabetes Metab 47(6):101285. https:\/\/doi.org\/10.1016\/j.diabet.2021.101285","journal-title":"Diabetes Metab"},{"issue":"1","key":"4625_CR29","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.cmet.2020.06.014","volume":"32","author":"A Verma","year":"2020","unstructured":"Verma A, Patel AB, Waikar SS (2020) SGLT2 inhibitor: not a traditional diuretic for heart failure. Cell Metab 32(1):13\u201314. https:\/\/doi.org\/10.1016\/j.cmet.2020.06.014","journal-title":"Cell Metab"},{"issue":"2","key":"4625_CR30","doi-asserted-by":"publisher","first-page":"101419","DOI":"10.1016\/j.diabet.2023.101419","volume":"49","author":"AJ Scheen","year":"2023","unstructured":"Scheen AJ, Bonnet F (2023) Efficacy and safety profile of SGLT2 inhibitors in the elderly: how is the benefit\/risk balance? Diabetes Metab 49(2):101419. https:\/\/doi.org\/10.1016\/j.diabet.2023.101419","journal-title":"Diabetes Metab"},{"issue":"12","key":"4625_CR31","doi-asserted-by":"publisher","first-page":"3538","DOI":"10.1111\/dom.15249","volume":"25","author":"D Yabe","year":"2023","unstructured":"Yabe D, Shiki K, Homma G, Meinicke T, Ogura Y, Seino Y et al (2023) Efficacy and safety of the sodium-glucose co-transporter-2 inhibitor empagliflozin in elderly Japanese adults (>\/=65 years) with type 2 diabetes: a randomized, double-blind, placebo-controlled, 52-week clinical trial (EMPA-ELDERLY). Diabetes Obes Metab 25(12):3538\u20133548. https:\/\/doi.org\/10.1111\/dom.15249","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"4625_CR32","doi-asserted-by":"publisher","first-page":"2963","DOI":"10.1111\/dom.15193","volume":"25","author":"M Rigato","year":"2023","unstructured":"Rigato M, Fadini GP, Avogaro A (2023) Safety of sodium-glucose cotransporter 2 inhibitors in elderly patients with type 2 diabetes: a meta-analysis of randomized controlled trials. Diabetes Obes Metab 25(10):2963\u20132969. https:\/\/doi.org\/10.1111\/dom.15193","journal-title":"Diabetes Obes Metab"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04625-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-025-04625-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04625-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T18:14:57Z","timestamp":1761848097000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-025-04625-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":32,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4625"],"URL":"https:\/\/doi.org\/10.1007\/s11255-025-04625-9","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"27 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"\u00d6zant Helvac\u0131 has received honoraria from Boehringer Ingelheim (empagliflozin) and AstraZeneca (dapagliflozin) for delivering educational lectures to healthcare professionals unrelated to the current study. Other authors reveal no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted in accordance with the 1964 Declaration of Helsinki. Ethical approval was obtained from the local Ethics Committee of Gazi University (E-77082166-604.01-921758). Informed consent was obtained from all participants prior to their inclusion in the study. Participants were assured of the confidentiality of their data and their right to withdraw from the study at any time without any consequences.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}